Quick answers
- What is Phenylephrine used for?
- The FDA-approved label (Phenylephrine Hydrochloride, Hikma Pharmaceuticals USA Inc., August 19, 2026) says: “IMMPHENTIV injection 100 mcg/mL is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Phenylephrine Hydrochloride Injection 10 mg/mL is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the settings of anesthesia and septic shock. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Phenylephrine have a boxed warning?
- No. None of the 57 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Phenylephrine?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Phenylephrine been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started March 11, 2021 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Phenylephrine?
- 37 companies list prescription products of Phenylephrine in the FDA NDC Directory, including Somerset Therapeutics, LLC, Lifestar Pharma LLC and Hikma Pharmaceuticals USA Inc..
What Phenylephrine is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
IMMPHENTIV injection 100 mcg/mL is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Phenylephrine Hydrochloride Injection 10 mg/mL is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the settings of anesthesia and septic shock. …
— FDA label: Phenylephrine Hydrochloride, Hikma Pharmaceuticals USA Inc., effective August 19, 2026. Read the full label on DailyMed →
The FDA has 57 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 57 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Injection · Solution/ drops · Injection, solution · Solution · Injectable, liposomal |
|---|---|
| Route | Intravenous · Ophthalmic |
| Prescription products | 113 in the FDA NDC Directory |
| Brand names | Biorphen, Immphentiv |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| phenylephrine hydrochloride 100 mg/mL solution | Generic | $5.27 per mL |
| phenylephrine hydrochloride 100 mg/mL solution/ drops | Generic | $5.27 per mL |
| phenylephrine hydrochloride 25 mg/mL solution | Generic | $9.08 per mL |
| phenylephrine hydrochloride 25 mg/mL solution/ drops | Generic | $9.08 per mL |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Somerset Therapeutics, LLC7 products
- Lifestar Pharma LLC7 products
- Hikma Pharmaceuticals USA Inc.6 products
- Sandoz Inc6 products
- Dr. Reddy's Laboratories Inc.6 products
- Medical Purchasing Solutions, LLC6 products
- Gland Pharma Limited6 products
- Caplin Steriles Limited6 products
- Fresenius Kabi USA, LLC4 products
- Novadoz Pharmaceuticals LLC3 products
- Hainan Poly Pharm. Co., Ltd.3 products
- Xellia Pharmaceuticals USA LLC3 products
- Method Pharmaceuticals, LLC3 products
- Amneal Pharmaceuticals LLC3 products
- Eugia US LLC3 products
- BE Pharmaceuticals Inc.3 products
- Armas Pharmaceuticals Inc.3 products
- Camber Pharmaceuticals, Inc.3 products
- Provepharm Inc.3 products
- Baxter Healthcare Corporation3 products
- Meitheal Pharmaceuticals Inc.2 products
- Paragon BioTeck, Inc.2 products
- Bausch & Lomb Americas Inc.2 products
- Par Health USA, LLC2 products
- HF Acquisition Co LLC, DBA HealthFirst2 products
- Alcon Laboratories, Inc.2 products
- Civica, Inc.2 products
- NorthStar RxLLC2 products
- SOLA Pharmaceuticals, LLC2 products
- First Nation Group, LLC2 products
- Leading Pharma, LLC2 products
- Sagent Pharmaceuticals1 product
- Cardinal Health 107, LLC1 product
- Henry Schein, Inc.1 product
- Medical Purhasing Solutions, LLC1 product
- ProPharma Distribution1 product
- Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA203510 PHENYLEPHRINE HYDROCHLORIDE | Paragon Bioteck | March 21, 2013 | 3, latest December 8, 2022 2022: Manufacturing (CMC) · 2020: Labeling · 2013: Manufacturing (CMC) |
| NDA203826 IMMPHENTIV, PHENYLEPHRINE HYDROCHLORIDE | Hikma | December 20, 2012 | 7, latest March 9, 2023 2023: Manufacturing (CMC) · 2023: Labeling · 2019: Manufacturing (CMC) |
| NDA207926 PHENYLEPHRINE HYDROCHLORIDE | Alcon | January 15, 2015 | 2, latest March 13, 2025 2025: Manufacturing (CMC) · 2019: Labeling |
| NDA212909 BIORPHEN | DR Reddys Labs SA | October 21, 2019 | 2, latest April 12, 2024 2024: Manufacturing (CMC) · 2021: Efficacy |
| NDA216830 PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | DR Reddys Labs SA | May 30, 2025 | — |
Generic approvals (25)
- ANDA210333Meitheal · April 27, 2018
- ANDA210334Meitheal · April 27, 2018
- ANDA211079Amneal · July 5, 2018
- ANDA211078Amneal · July 19, 2018
- ANDA210025Ph Health · December 21, 2018
- ANDA210665Fresenius Kabi USA · January 29, 2019
- ANDA210666Fresenius Kabi USA · January 30, 2019
- ANDA208905Sandoz · January 31, 2019
- ANDA209967Sagent Pharms Inc · January 16, 2020
- ANDA211920Gland · June 5, 2020
- ANDA213318Caplin · June 11, 2020
- ANDA211081Milla Pharms · July 17, 2020
- ANDA210697Eugia Pharma · November 13, 2020
- ANDA210696Eugia Pharma · January 7, 2021
- ANDA217069Mankind Pharma · August 30, 2022
- ANDA216859Mankind Pharma · September 29, 2022
- ANDA216496Mankind Pharma · January 11, 2023
- ANDA209968Avet Lifesciences · February 28, 2023
- ANDA217521Be Pharms · June 26, 2023
- ANDA218412Hainan Poly · March 14, 2024
- ANDA218110Aspiro · May 10, 2024
- ANDA215183Caplin · May 23, 2024
- ANDA218129Gland · December 18, 2024
- ANDA215617Somerset Theraps LLC · February 14, 2025
- ANDA217032Baxter Hlthcare Corp · April 3, 2026
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
March 11, 2021 · Class II · Terminated · D-0305-2021
Lack of Assurance of Sterility: customer complaints of loose crimped vial overseals which may result in a non-sterile product.
Phenylephrine HCl Injection, USP, 10 mg per mL, 1 mL per Single-Dose Vial packaged in 25 x 1 mL Single-Dose Vials per carton, For Intravenous Use, Rx only, Mfd. for: SAGENT Pharmaceuticals, Schaumburg, IL 60195; Made in — Sagent Pharmaceuticals Inc
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 1232651, 1234571, 1234579, 1666372, 2262018, 2533434, 2533437, 2634228, 2634233, 2634235 … (+1) |
|---|---|
| SPL set ID of the quoted label | e1a7ab4b-0afe-4463-a039-5be0323cf2f7 |
| FDA labels (SPL) | 57 |
| FDA applications | NDA203510, NDA203826, NDA207926, NDA212909, NDA216830, 25 ANDA |
| Active ingredients (FDA) | PHENYLEPHRINE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Phenylephrine Hydrochloride, Hikma Pharmaceuticals USA Inc., effective August 19, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →